Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma
Withdrawn before enrolling · Phase 2
Conditions studied: Melanoma (Skin)
In brief
RATIONALE: Interleukin-2 and sargramostim may stimulate a person's white blood cells to kill melanoma cells. PURPOSE: This phase II trial is studying how well giving interleukin-2 together with sargramostim works in treating patients with stage III or stage IV melanoma that was previously treated with chemotherapy.
Key facts
- Study ID
- NCT00085579
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 0
- Starts
- 2004-03-01
- Expected to finish
- 2005-03-01
- Last updated by the study team
- 2012-12-12
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.